Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose
Incidence rates were comparable to those among unvaccinated individuals Analysis of rare cases from global safety database published in The LancetRates of the very rare clotting disorder, thrombosis with thrombocytopenia syndrome (TTS), following a second dose of Vaxzevria are comparable to the background rate in an unvaccinated population. The data, published in The Lancet 01693-7/fulltext) today, demonstrated the estimated rate of TTS following a second dose of Vaxzevria was 2.3 per million vaccinees, comparable to